Vergote I, Laekeman G, Heiremans J, Becquart D, Buytaert P, Herman A
Tumour Biol. 1986;7(5-6):407-10.
In this study, 6-keto-prostaglandin F1 alpha, TXB2, and 15-keto-13,14-dihydro-prostaglandin F2 alpha plasma levels (i.e., theprostacyclin, thromboxane, and PGF2 alpha-metabolites, respectively) were determined, using a radioimmunoassay, in 32 breast cancer patients (21 without evidence of disease and 11 with metastases), and in a control group of 16 patients. Neither group of breast cancer patients showed an increased plasma level of any of these products compared with the control group. This study suggests that the increased 6-keto-prostaglandin F1 alpha, TXB2 and prostaglandin F2 alpha levels which have been observed in breast cancer tissues are not detectable in the plasma.
在本研究中，采用放射免疫分析法测定了32例乳腺癌患者（21例无疾病证据，11例有转移）及16例患者组成的对照组血浆中6-酮-前列腺素F1α、血栓素B2和15-酮-13,14-二氢-前列腺素F2α的水平（分别即前列环素、血栓烷和前列腺素F2α代谢物）。与对照组相比，两组乳腺癌患者均未表现出这些产物中任何一种的血浆水平升高。本研究表明，在乳腺癌组织中观察到的6-酮-前列腺素F1α、血栓素B2和前列腺素F2α水平升高在血浆中无法检测到。
